Massive dilution in addition to the upcoming reverse split and consistent trial/drug failures. Horrible management team. Horrible! I'll bet anything the upcoming reverse split will immediately be followed by a new share offering to raise capital to finance the new study needed because of the failed NDA.
News 
Market Data 
Discover 
AI
